DiaGenic ASA: Notice of Allowance of United States Family 3 Breast Cancer Patent
OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) has now received notice of allowance of the United States family 3 patent application (11/628,300). The claims allowed cover the use of some important gene sequences or the related proteins in blood sample for detection and monitoring of breast cancer in the US. The patent will be valid until 2025.